Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine

Fundamental and Clinical Pharmacology

Volumn 22, Issue 4, 2008, Pages 429-437

  Liang, Gong Wen ^a   Lu, Wan Liang ^a   Wu, Jin Wei ^a   Zhao, Ji Hui ^a   Hong, Hai Yan ^b   Long, Chuan ^a   Li, Ting ^a   Zhang, Yu Teng ^a   Zhang, Hua ^a   Wang, Jian Cheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Anti resistant tumor effects; Caspases; Leukemia; Stealthy liposomal vincristine plus quinacrine

Indexed keywords

CASPASE 3; CASPASE 9; LIPOSOME; MEPACRINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CASPASE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LIPOSOMAL DELIVERY; MOUSE; MULTIDRUG RESISTANCE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL LEUKEMIA; METABOLISM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, EXPERIMENTAL; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINACRINE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 55949105610     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00613.x     Document Type: Article

References (32)

1. Thomas D.A., Sarris A.H., Cortes J. et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer (2006) 106 120-127.
2. Diviné M., Casassus P., Koscielny S. et al., GELA; GOELAMS. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann. Oncol. (2005) 16 1928-1935.
3. Tulpule A., Espina B.M., Berman N. et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin. Lymphoma. Myeloma. (2006) 7 59-64.
4. Aviles A., Delgado S., Nambo M.J., Neri N., Murillo E., Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology (2005) 69 256-260.
5. Rosti G., Carminati O., Monti M., Tamberi S., Marangolo M. Chemotherapy advances in small cell lung cancer. Ann. Oncol. (2006) 17(Suppl 5) v99-v102.
6. Islam M.N., Iskander M.N. Microtubulin binding sites as target for developing anticancer agents. Mini. Rev. Med. Chem. (2004) 4 1077-1104.
7. Wang T.H., Wang H.S., Ichijo H. et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. (1998) 273 4928-4936.
8. Ruvolo P.P., Deng X., May W.S. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia (2001) 15 515-522.
9. Carta A., Loriga M., Piras S. et al. Synthesis of variously substituted 3-phenoxymethyl quinoxalin-2-ones and quinoxa-lines capable to potentiate in vitro the antiproliferative activity of anticancer drugs in multidrug resistant cell lines. Med. Chem. (2006) 2 113-122.
10. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Genetic analysis of the multi-drug transporter. Annu. Rev. Genet. (1995) 29 607-649.
11. Chen C.J., Chin J.E., Ueda K. et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47 381-389.
12. Cole S.P., Bhardwaj G., Gerlach J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258 1650-1654.
13. Gaj C.L., Anyanwutaku I., Chang Y.H., Cheng Y.C. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem. Pharmacol. (1998) 55 1199-1211.
14. Vanderweele D.J., Rudin C.M. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Mol. Cancer. Res. (2005) 3 635-644.
15. Fisher G.A., Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. (1995) 9 363-382.
16. Robert J. Approaches to multidrug resistance reversal. Expert. Opin. Investig. Drugs. (1998) 7 929-939.
17. de Souza P.L., Castillo M., Myers C.E. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br. J. Cancer. (1997) 75 1593-1600.
18. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. (1988) 33 454-462.
19. Inaba M., Maruyama E. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine. Cancer. Res. (1988) 48 2064-2067.
20. Li X., Ruan G.R., Lu W.L. et al. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced anti-tumor activity in leukemia. J. Control. Release. (2006) 112 186-198.
21. Yuan F., Salehi H.A., Boucher Y., Vasthare U.S., Tuma R.F., Jain R.K. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer. Res. (1994) 54 4564-4568.
22. Harrington K.J., Mohammadtaghi S., Uster P.S. et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer. Res. (2001) 7 243-254.
23. Hobbs S.K., Monsky W.L., Yuan F. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvi-ronment. Proc. Natl. Acad. Sci. USA (1998) 95 4607-4612.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. (1983) 65 55-63.
25. Liang Z.H., Wu P.H., Li L., Xue G., Zeng Y.X., Huang W.L. Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recom-binant endostatin protein. Chin. Med. J. (2004) 117 1809-1814.
26. Mori M., Terui Y., Tanaka M. et al. Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB. Cancer. Res. (2001) 61 4414-4417.
27. Sun P., Ren X.D., Zhang H.W. et al. Serum from rabbit orally administered cobra venom inhibits growth of implanted hepa-tocellular carcinoma cells in mice. World. J. Gastroenterol. (2003) 9 2441-2444.
28. Twomey C., McCarthy J.V. Pathways of apoptosis and importance in development. J. Cell. Mol. Med. (2005) 9 345-359.
29. Colbern G.T., Dykes D.J., Engbers C. et al. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer. Res. (1998) 4 3077-3082.
30. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer. Chemother. Pharmacol. (1999) 43 1-7.
31. Rowinsky E., Donhower R.C. Cancer chemotherapy and biotherapy, Lippincot-Raven Publishers, Philadelphia, 1996. pp. 263-275.
32. Scoazec J.Y., Krolak-Salmon P., Casez O. et al. Quinacrine induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. (2003) 53 546-547.